Moving forward, it would be valuable to analyze the correlation between PD-L1–expressing CTCs and other clinical parameters (e.g., tumor size, metastasis, and treatment response) to establish a more precise risk evaluation and develop individualized treatment strategies. The gene discussed is CD274; the disease is neoplasm.